Related Content
Download content relating to this event and topic.
Vaccine World Asia Congress 2026 - South East Asia
8th Edition
SEA'S ONLY VACCINE CONFERENCE FROM DISCOVERY TO DELIVERY
8th Vaccine World Asia Congress 2026 – South East Asia, stands to be an outstanding gathering of leading vaccine experts, researchers, regulators, policymakers, and industry leaders from the SEA region.
Jakarta, Indonesia
14
October
-
15
October
2026
00
Days
00
Hours
00
Mins
00
Secs
200
+
Attendees
Maximum Attendees
80
+
Companies
30
+
Speakers
16
+
Networking Hours
8
+
Case Studies
Interactive Sessions
About the Event
Building on the momentum of its successful edition, 8th Vaccine World Asia – Southeast Asia 2026 returns as the region’s most influential gathering for vaccine leaders, with a dedicated spotlight on Indonesia and the broader SEA vaccine ecosystem. As SEA experiences rising vaccine demand driven by persistent public health challenges—including dengue, hepatitis, tuberculosis, influenza, and emerging infectious diseases—governments are boosting investments in immunization programs, manufacturing capabilities, and resilient supply chains. Indonesia, one of the region’s largest and fastest-growing vaccine markets, continues to scale its national immunization efforts, strengthen domestic production, and advance collaborations to achieve vaccine self-sufficiency.
At the same time, SEA faces ongoing barriers such as fragmented regulatory pathways, supply chain bottlenecks, cold-chain limitations, decentralized healthcare infrastructure, and pockets of vaccine hesitancy—especially across rural and remote areas. Rapidly evolving technologies such as mRNA, recombinant platforms, viral vectors, thermostable formulations, and improved delivery systems are reshaping the region’s vaccine landscape, offering new pathways to bridge immunization gaps and enhance outbreak preparedness.
8th Vaccine World Asia Congress 2026 – Southeast Asia emerges as the go-to strategic event for vaccine leaders across SEA. The congress will spotlight critical pathways for unlocking regional growth, including strengthening domestic manufacturing, improving cross-border regulatory harmonization, expanding vaccination coverage, accelerating innovation in universal and next-generation vaccines, and modernizing production through digitalized, cost-efficient processes. By convening leading policymakers, manufacturers, researchers, global health organizations, and technology partners, the event serves as a catalyst for reshaping the future of vaccine development and immunization delivery throughout SEA.
Co-Located Events
Visit the event page to view more content.
Awards Cerermony
Visit the awards page to view more content.
Agenda at a Glance
View the Key Themes for
Vaccine World Asia Congress 2026 - South East Asia
Day 1 | October 14 2026
- Plenary Session: Building Southeast Asia’s Biologics & Vaccine Ecosystem
- Next-Generation Vaccine Discovery & Platform Technologies
- Clinical Trials & Regulatory Harmonization in SEA
- Scaling Biomanufacturing Capacity & Technology Transfer Across SEA
Awards Ceremony : AVEA2026
Day 2 | October 15 2026
- mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines
- Vaccine Showcase: Emerging & Re-Emerging Infectious Diseases in SEA
- Vaccine Distribution & Cold Chain
- Leadership Panel Discussion: Can Southeast Asia Become a Global Biomanufacturing Powerhouse?
Ready to attend?
Register today to secure your ticket.
Speakers
Esteemed Voices From the Industry
Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.
Dr. Mohd Azlan bin Zaharudin
Malaysian Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI)
Director
Malaysia
Dr. Mohd Azlan Bin Zaharudin is the Director of the Malaysian Vaccine Project Office (MVPO) under the Ministry of Science, Technology, and Innovation (MOSTI). In this role, he oversees the coordination and implementation of strategies related to Malaysia's National Vaccine Development Roadmap (NVDR). His responsibilities include leading efforts in vaccine ecosystem development and facilitating collaborations to advance vaccine innovation in Malaysia.
Prior to his role at MVPO, Dr. Mohd Azlan was part of the Strategic Technology and S&T Application Division of MOSTI, where he focused on the biotechnology sector. His work in this division provided him with valuable insights and experience that he now applies to his current position.
Advisory Board Commitee
Chairman
Dr. Mohd Azlan bin Zaharudin
Director
Malaysian Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI)
Malaysia
Advisory Board Commitee
Chairman
Rakhmat Budi Yuwono
Quality Director
Etana Technologies
Indonesia
Shanti Marlina Sibuea
The Indonesian FDA (Badan POM)
Acting Director, Directorate of Control of Production of Drug, Narcotic, Psychotropic and Precursor
Indonesia
Shanti Marlina Sibuea is the Acting Director of the Directorate of Production of Drug, Narcotic, Psychotropic and Precursor Control at the Indonesian FDA (Badan POM). With over 15 years of experience as a GMP inspector, she has led and participated in numerous international inspections across China, India, South Korea, Japan, and Puerto Rico. Her expertise spans regulatory systems, quality management, and oversight of biological products and advanced therapies. She serves as a PIC/S assessor and actively contributes to global regulatory convergence, including international regulatory assessments and expert circles on ATMPs. She holds a PhD from Monash University, focusing on stem cell and regenerative medicine, and supports national and regional capacity building in regulatory science.
Advisory Board Commitee
Chairman
Shanti Marlina Sibuea
Acting Director, Directorate of Control of Production of Drug, Narcotic, Psychotropic and Precursor
The Indonesian FDA (Badan POM)
Indonesia
Badarulhisam Abdul Rahman, PhD
Pharmaniaga Berhad
Chief Scientific Officer
Malaysia
Dr. Badarulhisam is currently the Chief Scientific Officer at Pharmaniaga Berhad. He is responsible to spearhead product development and regulatory strategies for the company, inclusive of product ideation, development, trial, registration and product life cycle management. Among others, he is currently leading the team for various biopharma and vaccine development program, either through in house development or through technology transfer from several international strategic partners.
Dr Badarulhisam qualified as a Biochemical Engineer. He received his PhD from the Johns Hopkins University, USA and MSc and Advanced Diploma from the University College of London, UK. His area of expertise is in the fields of Biochemical Engineering and Biotechnology. Dr. Badarulhisam developed his early career as a lecturer at the Department of Bioprocess Engineering, University Technology of Malaysia and he is still active academically. He has served as a Professor (adjunct) at Chemical Engineering Department, University Putra Malaysia and he is also a member for the Board of Academic Advisory, School of Pharmacy, Universiti Kebangsaan Malaysia and a few other universities. He has served as an industrial advisor to several Bioprocess Engineering Programs in major universities in Malaysia and co supervises Masters and PhD students in various aspects of Biopharmaceutical Plant Design, Biologics Drug Development and Process Optimizations.
Advisory Board Commitee
Chairman
Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer
Pharmaniaga Berhad
Malaysia
Want to Speak at This Event?
Join the roster of esteemed colleagues to discuss what you or your company are bringing to the biopharmaceutical industry.
Apply to SpeakRegistration
Select the relevant ticket for your organisation.
*Delegate tickets must be purchased under the correct classification.
Biopharma tickets are strictly reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own, or commercialise therapeutic drug products, including organisations with an internal drug pipeline spanning discovery, development, clinical, or commercial stages. This category applies to companies whose primary business is the development or manufacture of drug products, not the provision of enabling technologies, equipment, platforms, or services.
Service, Solution, and Technology Provider tickets apply to all organisations offering services, platforms, technologies, equipment, consultancy, manufacturing services, or commercial solutions to the pharma and biopharma industry. This includes, but is not limited to, CROs, CDMOs, technology and equipment vendors, consultants, suppliers, and solution providers, regardless of scientific or technical focus.
Important Notice
All registrations are reviewed to ensure correct classification. Purchasing an incorrect ticket does not guarantee entry to the event. IMAPAC retains full discretion to deny access, reclassify registrations, and issue an invoice for the price difference required for correct attendance. Incorrect ticket purchases made under an inappropriate classification are not eligible for refunds under any circumstances, including where the registrant chooses not to upgrade or attend.
BigPharma, BioPharmas, Academics (Asia)
SGD 2,095 (Final Call Rate)
Early Bird Rate : SGD 1,495
Use discount code: EARLYBIRD
(Valid until 15th May 2026)
Registration Open Rate : SGD 1,695
Use discount code: REGISTRATIONOPEN
(Valid until 17th July 2026)
Standard Rate : SGD 1,895
Use discount code: STANDARD
(Valid until 18th September 2026)
Final Call Rate : SGD 2,095
Applicable to company profiles (headquartered within the APAC region):
- BioPharma
- Academic Institutions
- Research Organisations
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations
BigPharma, BioPharmas, Academics (outside Asia)
SGD 2,595 (Final Call Rate)
Early Bird Rate : SGD 1,995
Use discount code: EARLYBIRD
(Valid until 15th May 2026)
Registration Open Rate : SGD 2,195
Use discount code: REGISTRATIONOPEN
(Valid until 17th July 2026)
Standard Rate : SGD 2,395
Use discount code: STANDARD
(Valid until 18th September 2026)
Final Call Rate : SGD 2,595
Applicable to company profiles (headquartered outside of the APAC region):
- BioPharma
- Academic Institutions
- Research Organisations
Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designation
Service & Solution Provider
SGD 3,595 (Final Call Rate)
Early Bird Rate : SGD 2,995
Use discount code: EARLYBIRD
(Valid until 15th May 2026)
Registration Open Rate : SGD 3,195
Use discount code: REGISTRATIONOPEN
(Valid until 17th July 2026)
Standard Rate : SGD 3,395
Use discount code: STANDARD
(Valid until 18th September 2026)
Final Call Rate : SGD 3,595
Applicable to company profiles:
- Technology, Service, and Solution Providers
- CDMO/ CMO
Job Profiles: Business Development, Marketing, and Sales
Registration
Register Your Interest
Be the first in line!
Register your interest to get access to tickets as soon as they go live.
Principal
No items found.
Platinum
No items found.
Gold
No items found.
Silver
No items found.
Bronze
No items found.
Exhibition & Showcase
Associate
.webp)
Media & Publicity
No items found.
Want to Sponsor This Event?
Contact the IMAPAC to learn about our sponsorship process, rates and more.
Pre Conference Workshops & Other Sessions
Visit the event page to view more content.
No items found.
.webp)
Frequently Asked Questions
How can I stay updated on event details and announcements?
To stay informed about event updates, including date, venue, and agenda, please subscribe to our our official social media channels for real-time updates and announcements.
What can I expect to learn and explore during the event?
The conference will provide a comprehensive learning experience covering various aspects of the dynamic biopharmaceutical industry, ensuring attendees gain valuable insights and knowledge.
What safety measures will be in place to ensure the safety of attendees?
We are committed to ensuring the safety and well-being of all attendees. We will implement rigorous safety measures in line with local health guidelines and regulations. Specific safety measures will be communicated closer to the event date to ensure they align with the most up-to-date health recommendations. Rest assured, your safety is our priority.
Can I submit a presentation to be a speaker at this event?
We welcome presentation submissions. If you’re interested in speaking at the event, please visit this page on our website for submission guidelines and deadlines.
What type of professionals benefit most from attending?
Our event is designed to cater to a wide range of professionals within the biopharmaceutical industry, including researchers, scientists, executives, regulatory experts, and professionals involved in drug development and manufacturing.
What advantages does this conference offer participants?
Participants can expect to gain insights from industry experts, network with peers, and stay up-to-date with the latest trends and innovations in biopharmaceuticals
Are there networking opportunities or special events planned?
Yes, we have networking sessions, workshops, and social events scheduled throughout the event to facilitate connections and collaborations among attendees.
Are there sponsorship opportunities for this event?
Yes, we offer sponsorship and exhibition opportunities for businesses and organisations.
How can I register for the event?
To register for the event, you'll find multiple "register" buttons on this page to get started. You’ll find detailed instructions and options for registration, including pricing and deadlines.
Be a Part of This Event!
Don't miss out on unique networking, speaking and sponsorship opportunities.